Skip to NavigationSkip to content

Pfizer appoints neuroscience research head

Published on: 10/06/10

Pfizer has appointed Dr Michael Ehlers chief scientific officer for neuroscience research.

Dr Ehlers most recently served as the George Barth Geller Professor in the Department of Neurobiology at Duke University and as an investigator with the Howard Hughes Medical Institute

Prior to this he served as the director of the neuroproteomics laboratory at Duke University.

He has authored over 60 scientific papers, and has been the recipient of numerous scientific awards, including the NARSAD Distinguished Investigator Award in 2009.

In his new role Dr Ehlers will report to Rod MacKenzie, senior vice president and head of PharmaTherapeutics Research & Development.

Dr MacKenzie said: “Mike is a world class scientist whose deep understanding of neurobiology will be a powerful asset as we build on the progress in our Neuroscience

Research Unit and apply new thinking to deliver novel therapeutics in Alzheimer’s disease, stroke, autism, and schizophrenia.

“His experience in the field and his passion for transforming medical outcomes are a winning combination in helping Pfizer create the industry’s leading pipeline of neuroscience medicines.”

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches